Latest Macular degeneration Stories
DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
A new study from the Mainz University Medical Center demonstrates that education and behavior play as large a role in the development of myopia, or nearsightedness, as genetic factors do.
TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment
Funding Critical on Diseases Now Affecting Baby Boomers CLARKSBURG, Md., July 11, 2014 /PRNewswire/ -- BrightFocus
First clinical trial of integrated approach underlines need for inclusion of behavior activation therapy in low vision rehabilitation SAN FRANCISCO, July 9, 2014 /PRNewswire-USNewswire/ --
Diopsys® NOVA-ERG provides a way to discriminate between AMD and healthy eyes. Pine Brook, NJ (PRWEB) July 01, 2014 In a controlled clinical study,
Professor Eberhart Zrenner Discusses the Future of Artificial Vision at Premier International Ophthalmology Meeting PARIS, June 30, 2014 /PRNewswire/ --
TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.